FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells
We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib. Fluorescence in situ hybridization specific for BCR-ABL1 and for FIP1L1-PDGFRA was combined with cytomorphology or with lineage-restricted monoclonal antibodies and applied in CML and CEL, respectively. In CEL the amount of FIP1L1-PDGFRA+ cells among CD34+ and CD133+ cells, B and T lymphocytes, and megakaryocytes were within normal ranges. Positivity was found in eosinophils, granulo-monocytes and varying percentages of erythrocytes. In vitro assays with imatinib showed reduced survival of peripheral blood mononuclear cells but no reduction in colony-forming unit growth medium (CFU-GM) growth. In CML the BCR-ABL1 fusion gene was detected in CD34+/CD133+ cells, granulo-monocytes, eosinophils, erythrocytes, megakaryocytes and B-lymphocytes. Growth of both peripheral blood mononuclear cells and CFU-GM was inhibited by imatinib. This study provided evidence for marked differences in the leukemic masses which are targeted by imatinib in CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1.
lymphocytes, eosinophils, glycophorin, receptor, growth, antigens, myeloproliferative disorders, protein kinase inhibitors, granulocytes, fusion proteins, in vitro, agents, oncogene proteins, cd34, bone marrow, comparative study, protein, bone marrow transplantation, research support, piperazines, chronic disease, leukemia, myelogenous, affect, t-lymphocytes, platelet-derived growth factor, genetics, blood, hypereosinophilic syndrome, tumor stem cell assay, mrna cleavage and polyadenylation factors, fluorescence, x chromosome inactivation, alpha, b-lymphocytes, antagonists & inhibitors, bcr-abl positive, drug therapy, hematopoietic stem cells, glycoproteins, multicenter studies, human, lymphocyte subsets, in-vitro, therapeutic use, clone cells, drug resistance, fusion, cell lineage, antibodies, pathology, platelet-derived growth factor alpha, cd, neoplastic stem cells, antineoplastic agents, myeloid cells, survival, megakaryocytes, monocytes, chronic, bcr-abl, research, enzymology, analysis, transplantation, immunophenotyping, humans, bone, in situ hybridization, proteins, erythrocytes, pyrimidines, peptides
397-402
Crescenzi, B.
a48526a2-1af0-4304-92d5-35f61aa90886
Chase, A.
a40a09c2-3073-4655-ba0b-a802e34914b5
Starza, R.L.
8a5c03cb-8f60-4ccb-94f9-cec3cbec10dd
Beacci, D.
da36e6b1-b19a-4db3-ba32-3536d9d5e3ce
Rosti, V.
686e0159-b5eb-44b8-8ee1-4c45c93e5cab
Galli, A.
4da0ed72-21ac-4d40-8165-88e8bfcb0127
Specchia, G.
618085e0-281f-4bab-a361-58d833175c74
Martelli, M.F.
4447aca8-62bb-437b-8044-3436da788f22
Vandenberghe, P.
382c88a8-a6c9-4527-a390-af7d1cbc4341
Cools, J.
ca24d9ad-d95b-46a8-b92c-bb49e896aab2
Jones, A.V.
daa5d0cf-4454-48c3-abb8-daf03aa21e8b
Cross, N.C.
f87650da-b908-4a34-b31b-d62c5f186fe4
Marynen, P.
fe45b010-1c84-4514-bd51-c97be31a498e
Mecucci, C.
2bd5a6ae-507a-438f-b8fa-ea67e67b0d5b
11 January 2007
Crescenzi, B.
a48526a2-1af0-4304-92d5-35f61aa90886
Chase, A.
a40a09c2-3073-4655-ba0b-a802e34914b5
Starza, R.L.
8a5c03cb-8f60-4ccb-94f9-cec3cbec10dd
Beacci, D.
da36e6b1-b19a-4db3-ba32-3536d9d5e3ce
Rosti, V.
686e0159-b5eb-44b8-8ee1-4c45c93e5cab
Galli, A.
4da0ed72-21ac-4d40-8165-88e8bfcb0127
Specchia, G.
618085e0-281f-4bab-a361-58d833175c74
Martelli, M.F.
4447aca8-62bb-437b-8044-3436da788f22
Vandenberghe, P.
382c88a8-a6c9-4527-a390-af7d1cbc4341
Cools, J.
ca24d9ad-d95b-46a8-b92c-bb49e896aab2
Jones, A.V.
daa5d0cf-4454-48c3-abb8-daf03aa21e8b
Cross, N.C.
f87650da-b908-4a34-b31b-d62c5f186fe4
Marynen, P.
fe45b010-1c84-4514-bd51-c97be31a498e
Mecucci, C.
2bd5a6ae-507a-438f-b8fa-ea67e67b0d5b